0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

ACE Inhibitors as a Shield Against Diabetic Nephropathy

Barry J. Materson, MD, MBA
Arch Intern Med. 1996;156(3):239-240. doi:10.1001/archinte.1996.00440030017002.
Text Size: A A A
Published online

FEW READERS of the Archives would be surprised by the statistic that about one third of all cases of end-stage renal disease are caused by diabetes mellitus. Yet, despite the advances in the treatment of diabetes that have evolved over more than half a century since insulin became available as a therapeutic agent, little progress had been made toward the protection of the kidneys as a target for diabetic microvascular disease. Very tight control of plasma glucose levels appears to offer protection, but at a cost of increased risk for hypoglycemic reactions.1 The use of computer-based algorithms, insulin pumps, and islet cell transplantations may reduce the risk of tight control while retaining its benefits, but the cost will be high and not all diabetic patients will have access to these modalities.2

The demonstration by Lewis et al3 that the angiotensin-converting enzyme (ACE) inhibitor captopril could delay or

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

* * SCHEDULED MAINTENANCE * *

Our websites may be periodically unavailable between midnight and 04:00 ET Thursday, July 10th, for regularly scheduled maintenance.

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 7

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();